GlassScriptPhysician profile
H Bianca Japal
NPI 1194724294
$3,748.03
in general payments reported to CMS, 2019-2025
20 companies · $568 in 2025
The $568 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $815 · 2020: $550 · 2021: $487 · 2022: $508 · 2023: $448 · 2024: $373 · 2025: $568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,389.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,477.85 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $413.41 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $259.89 | 2019-2022 | |
| Lilly USA, LLC | $228.10 | 2019-2024 | Jaypirca, Mounjaro, Jardiance |
| Merck Sharp & Dohme LLC | $219.02 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $210.14 | 2019-2024 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $176.55 | 2019-2025 | Rexulti |
| Allergan, INC. | $126.05 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $97.84 | 2022 | |
| Novartis Pharmaceuticals Corporation | $92.75 | 2019-2020 | |
| Novo Nordisk INC | $84.82 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $70.64 | 2019-2021 | |
| Glaxosmithkline, LLC. | $64.14 | 2020-2024 | Trelegy Ellipta, Arexvy |
| Sunovion Pharmaceuticals INC. | $63.31 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.10 | 2024-2025 | Caplyta |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $37.90 | 2025 | Repatha |
| Arbor Pharmaceuticals, INC. | $22.05 | 2019 | |
| Exact Sciences Corporation | $20.84 | 2025 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $16.67 | 2025 | Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $14.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw H Bianca Japal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.